Utbildningar migrän
Videopresentationer
Clinical use of a-CGRP treatments – Reasoning at the Danish Headache Center
Dr. Lars Bendtsen berättar om vilka kliniska erfarenheter av olika behandlingar med anti-CGRP-terapier som hittills gjorts på Danish Headache Center.
Migraine and Medication Overuse Headache
Prof. Dr. Koen Paemeleire, Ghent University Hospital, Belgien, presenterar riskfaktorer hos migränpatienter att utveckla kronisk migrän samt hur de angriper läkemedelsutlöst huvudvärk.
Informationsvideo om neurologiska sjukdomar under COVID-19 pandemin (SARS-CoV-2)
Dr. Sahin, Ph.D. Skåneuro AB och Dr. Özkaya Sahin, Ph.D. Lunds Universitetssjukhus
Insights into Sleep Habits, Sleep Disorders and Headache Disorders
Dr Baruch El-Ad, Neurology and Sleep Medicine, Tel Aviv-Yafo, Israel
Calcitonin gene-related protein (CGRP) in peripheral and central sensitisation
Anthony Dickenson, Professor, University College London, UK
Epidemiology, clinical manifestations and the burden of disease
Mattias Linde, MD, PhD, Professor
Preventive treatment of migraine, now and in the future
Lars Bendtsen, MD, PhD, Dr Med Sci
European Headache Federation guideline on the use of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for migraine prevention
Lars Bendtsen, MD, PhD, Dr Med Sci
Scientific meetings
Anti-CGRPs, from Molecule to Man
This meeting was held in Copenhagen, 29-30 november 2019
Brief summary from the migraine symposium
TEVA Nordics has since 2013 arranged an annual scientific symposium within multiple sclerosis intended to be complementary to other international congresses and with highest clinical and scientific relevance.
The topics and speakers have been selected by a Steering Committee consisting of leading migraine experts from each Nordic country.
Contact
If you have any questions regarding these symposiums, please contact your local Teva medical representative in Sweden: Fredrik Blomstrand / fredrik.blomstrand@teva.se
If you have any questions regarding these symposiums, please contact your local Teva medical representative in Sweden: Fredrik Blomstrand / fredrik.blomstrand@teva.se
Senast uppdaterad 15 februari 2021